The ADC binds to an epitope on the HER3 receptor, so that the binding is unaffected by NRG1 levels. Credit: Huen Structure Bio/Shutterstock.com.

Endeavor BioMedicines has acquired exclusive global rights to the HER3-targeted antibody-drug conjugate (ADC) from Hummingbird Bio, HMBD-501.

The next-generation ADC HMBD-501 is generated by Hummingbird Bio’s antibody discovery and engineering platform using ADC technologies for an improved safety and efficacy profile.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

HMBD-501 binds to an epitope on the HER3 receptor with the binding unaffected by NRG1 (HER3 ligand) levels. This allows attachment to HER3-expressing tumours even in high ligand contexts.

Endeavor BioMedicines co-founder, CEO and chairman John Hood stated: “This exclusive licence with Hummingbird Bio provides Endeavor with a potential best-in-class HER3-ADC, with the opportunity to treat a large number of patients in multiple tumour types.

“HER3 is more broadly expressed on tumours than HER2 and is expressed on tumours that do not express HER2.

“This next-generation ADC has the potential to address significant unmet clinical needs in areas left behind by HER2 agents.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Endeavor BioMedicines will make upfront and milestone payments of $430m to Hummingbird, which is also entitled to receive royalties on net sales.

Hummingbird Bio co-founder and CEO Piers Ingram said: “Hummingbird Bio has designed HMBD-501 to have a wider therapeutic index than current HER3 ADCs, maximising the potential clinical benefit for patients, and we are delighted that Endeavor has recognised the potential of this ADC built with our proprietary antibody technology.

“We are pleased to license HMBD-501 to the experienced Endeavor team to bring the molecule into the clinic and a step closer to benefiting patients.”